Point72 Hong Kong Ltd Takes Position in Genmab A/S (NASDAQ:GMAB)

Point72 Hong Kong Ltd purchased a new stake in Genmab A/S (NASDAQ:GMAB) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 43,671 shares of the company’s stock, valued at approximately $911,000.

A number of other hedge funds also recently made changes to their positions in GMAB. Crossmark Global Holdings Inc. boosted its stake in shares of Genmab A/S by 8.8% in the 4th quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company’s stock valued at $868,000 after purchasing an additional 3,377 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Genmab A/S by 82.7% in the 4th quarter. SG Americas Securities LLC now owns 26,396 shares of the company’s stock valued at $551,000 after purchasing an additional 11,949 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Genmab A/S by 33.4% in the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock valued at $120,000 after purchasing an additional 1,442 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Genmab A/S in the 4th quarter valued at approximately $93,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after purchasing an additional 827 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Genmab A/S stock opened at $19.65 on Friday. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $30.06. The firm has a 50 day moving average price of $19.75 and a two-hundred day moving average price of $20.79. The firm has a market cap of $12.60 billion, a price-to-earnings ratio of 11.29, a PEG ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The firm had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. As a group, equities research analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GMAB. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Sanford C. Bernstein downgraded shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus target price of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.